Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline

Vermersch P.; Giovannoni G.; Soelberg-Sorensen P.; Keller B.; Jack D.

首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline

【24h】

Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline

机译：在基线高疾病活性（HDA）患者中，在切换到从Cladribine片剂的克拉吡汀片剂进行安慰剂治疗的持续疗效

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Multiple sclerosis: clinical and laboratory research》 |2019年第3期|共2页
作者
Vermersch P.; Giovannoni G.; Soelberg-Sorensen P.; Keller B.; Jack D.;
展开▼
作者单位

Univ Lille CHU Lille LIRIC INSERM U995 FHU Imminent Lille Lille France;

Queen Mary Univ London Blizard Inst Barts &

London Sch Med &

Dent London England;

Univ Copenhagen Dept Neurol Danish MS Ctr Rigshosp Copenhagen Denmark;

Merck KGaA Darmstadt Germany;

Merck KGaA Darmstadt Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline [J] . Vermersch P., Giovannoni G., Soelberg-Sorensen P., Multiple sclerosis: clinical and laboratory research . 2019,第3期

机译：在基线高疾病活性（HDA）患者中，在切换到从Cladribine片剂的克拉吡汀片剂进行安慰剂治疗的持续疗效
2. Efficacy of cladribine tablets 3.5 mg/kg in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY study [J] . Giovannoni Gavin, Rammohan Kottil, Cook Stuart, Multiple sclerosis: clinical and laboratory research . 2018,第2期

机译：在清晰研究中复发多发性硬化症（RMS）的患者的高疾病活动（HDA）亚组中的克拉酮药片3.5mg / kg的疗效
3. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches [J] . Berardi Andrea, Siddiqui Mohd Kashif, Treharne Catrin, Current medical research and opinion . 2019,第8期

机译：估计克拉酮片剂与替代疾病修饰治疗的对比疗效在活性复发型多发性硬化症中：使用元回归调整患者特征和匹配调整的间接治疗比较方法
4. CNN Prediction of Future Disease Activity for Multiple Sclerosis Patients from Baseline MRI and Lesion Labels [C] . Nazanin Mohammadi Sepahvand, Tal Hassner, Douglas L. Arnold, International Workshop on Brainlesion . 2019

机译：基线MRI和病变标签的多发性硬化患者未来疾病活动的CNN预测
5. An investigation of early relapsing-remitting multiple sclerosis patients using diffusion tensor imaging and spectroscopy. [D] . Zaini, Wan Hazlin. 2013

机译：使用扩散张量成像和光谱法对早期复发缓解型多发性硬化症患者进行调查。
6. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study [O] . Giancarlo Comi, Stuart Cook, Kottil Rammohan, 2018

机译：克拉屈滨片对复发缓解型多发性硬化症患者MRI活动结局的长期影响：CLARITY Extension研究
7. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods [O] . Helen Bell Gorrod, Nicholas R. Latimer, Doris Damian, 2019

机译：使用治疗开关调整方法评估覆盖覆盖覆盖多发性硬化透明度随机对照试验和清晰度延伸的克拉替韦氏菌与安慰剂的长期效果

Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline

著录项

相似文献

相关主题

期刊订阅